| Year |
Citation |
Score |
| 2020 |
DeMets DL, Fleming TR. Achieving Effective Informed Oversight by DMCs in COVID Clinical Trials. Journal of Clinical Epidemiology. PMID 32659363 DOI: 10.1016/J.Jclinepi.2020.07.001 |
0.39 |
|
| 2020 |
Bhatnagar V, Hudgens S, Piault-Louis E, Jones L, Beaver JA, Lyerly HK, Reaman G, Fleming T, Kluetz PG. Patient-Reported Outcomes in Oncology Clinical Trials: Stakeholder Perspectives from the Accelerating Anticancer Agent Development and Validation Workshop 2019. The Oncologist. PMID 32463153 DOI: 10.1634/Theoncologist.2020-0062 |
0.36 |
|
| 2020 |
Dean NE, Gsell PS, Brookmeyer R, Crawford FW, Donnelly CA, Ellenberg SS, Fleming TR, Halloran ME, Horby P, Jaki T, Krause PR, Longini IM, Mulangu S, Muyembe-Tamfum JJ, Nason MC, et al. Creating a Framework for Conducting Randomized Clinical Trials during Disease Outbreaks. The New England Journal of Medicine. 382: 1366-1369. PMID 32242365 DOI: 10.1056/Nejmsb1905390 |
0.322 |
|
| 2019 |
Fleming TR, DeGruttola V, Donnell D. Designing & Conducting Trials To Reliably Evaluate HIV Prevention Interventions. Statistical Communications in Infectious Diseases. 11. PMID 33777327 DOI: 10.1515/Scid-2019-0001 |
0.374 |
|
| 2019 |
Giles JT, Sattar N, Gabriel S, Ridker PM, Gay S, Warne C, Musselman D, Brockwell L, Shittu E, Klearman M, Fleming TR. Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial. Arthritis & Rheumatology (Hoboken, N.J.). PMID 31469238 DOI: 10.1002/Art.41095 |
0.303 |
|
| 2018 |
Fleming TR, Ellenberg SS, DeMets DL. Data Monitoring Committees: Current issues. Clinical Trials (London, England). 1740774518764855. PMID 29629815 DOI: 10.1177/1740774518764855 |
0.379 |
|
| 2017 |
Fleming TR, DeMets DL, Roe MT, Wittes J, Calis KA, Vora AN, Meisel A, Bain RP, Konstam MA, Pencina MJ, Gordon DJ, Mahaffey KW, Hennekens CH, Neaton JD, Pearson GD, et al. Data monitoring committees: Promoting best practices to address emerging challenges. Clinical Trials (London, England). 14: 115-123. PMID 28359194 DOI: 10.1177/1740774516688915 |
0.319 |
|
| 2016 |
Fleming TR, Ellenberg SS. Evaluating interventions for Ebola: The need for randomized trials. Clinical Trials (London, England). 13: 6-9. PMID 26768563 DOI: 10.1177/1740774515616944 |
0.334 |
|
| 2015 |
Odem-Davis K, Fleming TR. A Simulation Study Evaluating Bio-Creep Risk in Serial Noninferiority Clinical Trials for Preservation of Effect Statistics in Biopharmaceutical Research. 7: 12-24. PMID 26052374 DOI: 10.1080/19466315.2014.1002627 |
0.358 |
|
| 2015 |
Fleming TR. Protecting the confidentiality of interim data: addressing current challenges. Clinical Trials (London, England). 12: 5-11. PMID 25475877 DOI: 10.1177/1740774514561243 |
0.393 |
|
| 2014 |
Fleming TR, Hennekens CH, Pfeffer MA, DeMets DL. Enhancing trial integrity by protecting the independence of data monitoring committees in clinical trials. Journal of Biopharmaceutical Statistics. 24: 968-75. PMID 24926941 DOI: 10.1080/10543406.2014.925719 |
0.384 |
|
| 2014 |
Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost A, Engel P, Kramer MR, Serdarevic-Pehar M, Layton GR, Sitbon O, Badesch DB. Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension. The Journal of Heart and Lung Transplantation : the Official Publication of the International Society For Heart Transplantation. 33: 689-97. PMID 24815795 DOI: 10.1016/J.Healun.2014.02.019 |
0.366 |
|
| 2013 |
Powers JH, Fleming TR. Noninferiority trials: clinical understandings and misunderstandings. Clinical Investigation. 3: 215-218. PMID 24563733 DOI: 10.4155/Cli.12.157 |
0.399 |
|
| 2013 |
Donnell D, Hughes JP, Wang L, Chen YQ, Fleming TR. Study design considerations for evaluating efficacy of systemic preexposure prophylaxis interventions. Journal of Acquired Immune Deficiency Syndromes (1999). 63: S130-4. PMID 23764624 DOI: 10.1097/Qai.0B013E3182986Fac |
0.301 |
|
| 2013 |
Raghu G, Collard HR, Anstrom KJ, Flaherty KR, Fleming TR, King TE, Martinez FJ, Brown KK. Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials. American Journal of Respiratory and Critical Care Medicine. 187: 1272. PMID 23725623 DOI: 10.1164/Rccm.201304-0712Le |
0.334 |
|
| 2013 |
Richardson BA, Kelly C, Ramjee G, Fleming T, Makanani B, Roberts S, Musara P, Mkandawire N, Moench T, Coletti A, Soto-Torres L, Karim SA. Appropriateness of hydroxyethylcellulose gel as a placebo control in vaginal microbicide trials: a comparison of the two control arms of HPTN 035. Journal of Acquired Immune Deficiency Syndromes (1999). 63: 120-5. PMID 23334506 DOI: 10.1097/Qai.0B013E31828607C5 |
0.325 |
|
| 2013 |
Carroll KJ, Fleming TR. Statistical Evaluation and Analysis of Regional Interactions: The PLATO Trial Case Study Statistics in Biopharmaceutical Research. 5: 91-101. DOI: 10.1080/19466315.2013.783878 |
0.389 |
|
| 2013 |
Hendriksz C, Burton BK, Fleming T, Giugliani R, Harmatz P, Hughes D, Jones S, Lin S, Mengel KE, Scarpa M, Valayannopoulos V. A multi-national, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of BMN 110 treatment for mucopolysaccharidosis IVA (Morquio syndrome type A) Molecular Genetics and Metabolism. 108. DOI: 10.1016/J.Ymgme.2012.11.110 |
0.302 |
|
| 2012 |
Chen YQ, Masse B, Wang L, Ou SS, Li X, Donnell D, McCauley M, Gamble T, Ribauldo HJ, Cohen MS, Fleming TR. Statistical considerations for the HPTN 052 Study to evaluate the effectiveness of early versus delayed antiretroviral strategies to prevent the sexual transmission of HIV-1 in serodiscordant couples. Contemporary Clinical Trials. 33: 1280-6. PMID 22813645 DOI: 10.1016/J.Cct.2012.07.007 |
0.302 |
|
| 2012 |
Talbot GH, Powers JH, Fleming TR, Siuciak JA, Bradley J, Boucher H. Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes of Health. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 55: 1114-21. PMID 22744885 DOI: 10.1093/Cid/Cis566 |
0.37 |
|
| 2012 |
Rothmann MD, Zhang JJ, Lu L, Fleming TR. Testing in a Prespecified Subgroup and the Intent-to-Treat Population. Drug Information Journal. 46: 175-179. PMID 22723719 DOI: 10.1177/0092861512436579 |
0.313 |
|
| 2012 |
Fleming TR, Powers JH. Biomarkers and surrogate endpoints in clinical trials. Statistics in Medicine. 31: 2973-84. PMID 22711298 DOI: 10.1002/Sim.5403 |
0.367 |
|
| 2012 |
Raghu G, Collard HR, Anstrom KJ, Flaherty KR, Fleming TR, King TE, Martinez FJ, Brown KK. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. American Journal of Respiratory and Critical Care Medicine. 185: 1044-8. PMID 22505745 DOI: 10.1164/Rccm.201201-0006Pp |
0.374 |
|
| 2011 |
Fleming TR, Odem-Davis K, Rothmann MD, Li Shen Y. Some essential considerations in the design and conduct of non-inferiority trials. Clinical Trials (London, England). 8: 432-9. PMID 21835862 DOI: 10.1177/1740774511410994 |
0.384 |
|
| 2011 |
Rubin LJ, Badesch DB, Fleming TR, Galiè N, Simonneau G, Ghofrani HA, Oakes M, Layton G, Serdarevic-Pehar M, McLaughlin VV, Barst RJ. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Chest. 140: 1274-83. PMID 21546436 DOI: 10.1378/Chest.10-0969 |
0.378 |
|
| 2011 |
Al-Khalidi HR, Hong Y, Fleming TR, Therneau TM. Insights on the robust variance estimator under recurrent-events model. Biometrics. 67: 1564-72. PMID 21418051 DOI: 10.1111/J.1541-0420.2011.01589.X |
0.353 |
|
| 2011 |
Fleming TR. Addressing missing data in clinical trials. Annals of Internal Medicine. 154: 113-7. PMID 21242367 DOI: 10.7326/0003-4819-154-2-201101180-00010 |
0.369 |
|
| 2010 |
Donnell D, Hughes JP, Fleming TR. Challenges in the design of HIV prevention trials in the United States. Journal of Acquired Immune Deficiency Syndromes (1999). 55: S136-40. PMID 21406984 DOI: 10.1097/Qai.0B013E3181Fbcb61 |
0.313 |
|
| 2010 |
Emerson SS, Fleming TR. Adaptive methods: telling "the rest of the story". Journal of Biopharmaceutical Statistics. 20: 1150-65. PMID 21058111 DOI: 10.1080/10543406.2010.514457 |
0.359 |
|
| 2010 |
Ellenberg SS, DeMets DL, Fleming TR. Bias and trials stopped early for benefit. Jama. 304: 158; author reply 15. PMID 20628127 DOI: 10.1001/Jama.2010.933 |
0.362 |
|
| 2009 |
McLaughlin VV, Badesch DB, Delcroix M, Fleming TR, Gaine SP, Galiè N, Gibbs JS, Kim NH, Oudiz RJ, Peacock A, Provencher S, Sitbon O, Tapson VF, Seeger W. End points and clinical trial design in pulmonary arterial hypertension. Journal of the American College of Cardiology. 54: S97-107. PMID 19555863 DOI: 10.1016/J.Jacc.2009.04.007 |
0.374 |
|
| 2009 |
Fleming TR, Rothmann MD, Lu HL. Issues in using progression-free survival when evaluating oncology products. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2874-80. PMID 19414672 DOI: 10.1200/Jco.2008.20.4107 |
0.402 |
|
| 2008 |
Fleming TR, Powers JH. Issues in noninferiority trials: the evidence in community-acquired pneumonia. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 47: S108-20. PMID 18986275 DOI: 10.1086/591390 |
0.37 |
|
| 2008 |
Spellberg B, Fleming TR, Gilbert DN. Executive summary: workshop on issues in the design and conduct of clinical trials of antibacterial drugs in the treatment of community-acquired pneumonia. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 47: S105-7. PMID 18986274 DOI: 10.1086/591389 |
0.43 |
|
| 2008 |
Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, Cossons N, Sitbon O, Badesch DB. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Annals of Internal Medicine. 149: 521-30. PMID 18936500 DOI: 10.7326/0003-4819-149-8-200810210-00004 |
0.348 |
|
| 2008 |
Fleming TR. Identifying and addressing safety signals in clinical trials. The New England Journal of Medicine. 359: 1400-2. PMID 18768938 DOI: 10.1056/Nejme0807372 |
0.349 |
|
| 2008 |
Jackson K, Gersh BJ, Stockbridge N, Fleming TR, Temple R, Califf RM, Connolly SJ, Wallentin L, Granger CB. Antithrombotic drug development for atrial fibrillation: proceedings, Washington, DC, July 25-27, 2005. American Heart Journal. 155: 829-40. PMID 18440329 DOI: 10.1016/J.Ahj.2008.01.023 |
0.385 |
|
| 2008 |
Fleming TR, Sharples K, McCall J, Moore A, Rodgers A, Stewart R. Maintaining confidentiality of interim data to enhance trial integrity and credibility. Clinical Trials (London, England). 5: 157-67. PMID 18375654 DOI: 10.1177/1740774508089459 |
0.392 |
|
| 2008 |
Ratain MJ, Humphrey RW, Gordon GB, Fyfe G, Adamson PC, Fleming TR, Stadler WM, Berry DA, Peck CC. Recommended changes to oncology clinical trial design: revolution or evolution? European Journal of Cancer (Oxford, England : 1990). 44: 8-11. PMID 17981025 DOI: 10.1016/J.Ejca.2007.09.011 |
0.381 |
|
| 2008 |
Fleming TR. Current issues in non-inferiority trials. Statistics in Medicine. 27: 317-32. PMID 17340597 DOI: 10.1002/Sim.2855 |
0.39 |
|
| 2007 |
Macmillan ML, Couriel D, Weisdorf DJ, Schwab G, Havrilla N, Fleming TR, Huang S, Roskos L, Slavin S, Shadduck RK, Dipersio J, Territo M, Pavletic S, Linker C, Heslop HE, et al. A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood. 109: 2657-62. PMID 17110457 DOI: 10.1182/Blood-2006-08-013995 |
0.385 |
|
| 2006 |
Fleming TR. Standard versus adaptive monitoring procedures: A commentary. Statistics in Medicine. 25: 3305-12; discussion . PMID 16850447 DOI: 10.1002/Sim.2641 |
0.376 |
|
| 2006 |
Yang P, Fleming TR. Simultaneous use of weighted logrank and standardized Kaplan-Meier statistics. Journal of Biopharmaceutical Statistics. 16: 241-52. PMID 16584070 DOI: 10.1080/10543400500508952 |
0.322 |
|
| 2006 |
Kollef M, Pittet D, Sánchez García M, Chastre J, Fagon JY, Bonten M, Hyzy R, Fleming TR, Fuchs H, Bellm L, Mercat A, Mañez R, Martínez A, Eggimann P, Daguerre M, et al. A randomized double-blind trial of iseganan in prevention of ventilator-associated pneumonia. American Journal of Respiratory and Critical Care Medicine. 173: 91-7. PMID 16192451 DOI: 10.1164/Rccm.200504-656Oc |
0.385 |
|
| 2006 |
Fleming TR. Evaluating the safety of interventions for prevention of perinatal transmission of HIV. Annals of the New York Academy of Sciences. 918: 201-211. PMID 11131706 DOI: 10.1111/J.1749-6632.2000.Tb05490.X |
0.339 |
|
| 2005 |
Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G. Sildenafil citrate therapy for pulmonary arterial hypertension. The New England Journal of Medicine. 353: 2148-57. PMID 16291984 DOI: 10.1056/Nejmoa050010 |
0.315 |
|
| 2005 |
Fleming TR. Objective response rate as a surrogate end point: a commentary. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 4845-6. PMID 15955898 DOI: 10.1200/Jco.2005.92.008 |
0.371 |
|
| 2005 |
Fleming TR. Surrogate endpoints and FDA's accelerated approval process. Health Affairs (Project Hope). 24: 67-78. PMID 15647217 DOI: 10.1377/Hlthaff.24.1.67 |
0.302 |
|
| 2004 |
DeMets DL, Fleming TR, Rockhold F, Massie B, Merchant T, Meisel A, Mishkin B, Wittes J, Stump D, Califf R. Liability issues for data monitoring committee members. Clinical Trials (London, England). 1: 525-31. PMID 16279293 DOI: 10.1191/1740774504Cn54Oa |
0.325 |
|
| 2004 |
Fleming TR, Richardson BA. Some design issues in trials of microbicides for the prevention of HIV infection Journal of Infectious Diseases. 190: 666-674. PMID 15272392 DOI: 10.1086/422603 |
0.382 |
|
| 2004 |
DeMets DL, Fleming TR. The independent statistician for data monitoring committees. Statistics in Medicine. 23: 1513-7. PMID 15122729 DOI: 10.1002/Sim.1786 |
0.389 |
|
| 2004 |
Giles FJ, Rodriguez R, Weisdorf D, Wingard JR, Martin PJ, Fleming TR, Goldberg SL, Anaissie EJ, Bolwell BJ, Chao NJ, Shea TC, Brunvand MM, Vaughan W, Petersen F, Schubert M, et al. A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. Leukemia Research. 28: 559-65. PMID 15120931 DOI: 10.1016/J.Leukres.2003.10.021 |
0.374 |
|
| 2004 |
Fleming T, Nissen SE, Borer JS, Armstrong PW. Report from the 100th Cardiovascular and Renal Drugs Advisory Committee meeting: US Food and Drug Administration: December 8-9, 2003 Gaithersburg, MD. Circulation. 109. PMID 14734515 DOI: 10.1161/01.Cir.0000118364.89571.16 |
0.372 |
|
| 2004 |
Wilson CM, Gray G, Read JS, Mwatha A, Lala S, Johnson S, Violari A, Sibiya PM, Fleming TR, Koonce A, Vermund SH, McIntyre J. Tolerance and safety of different concentrations of chlorhexidine for peripartum vaginal and infant washes: HIVNET 025. Journal of Acquired Immune Deficiency Syndromes (1999). 35: 138-43. PMID 14722445 DOI: 10.1097/00126334-200402010-00006 |
0.305 |
|
| 2003 |
Giles FJ, Miller CB, Hurd DD, Wingard JR, Fleming TR, Sonis ST, Bradford WZ, Pulliam JG, Anaissie EJ, Beveridge RA, Brunvand MM, Martin PJ, Bertz H, Clark R, Couriel DR, et al. A phase III, randomized, double-blind, placebo-controlled, multinational trial of Iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT Trial) Leukemia and Lymphoma. 44: 1165-1172. PMID 12916869 DOI: 10.1080/1042819031000079159 |
0.373 |
|
| 2002 |
Fleming TR, Ellenberg S, DeMets DL. Monitoring clinical trials: issues and controversies regarding confidentiality. Statistics in Medicine. 21: 2843-51. PMID 12325100 DOI: 10.1002/Sim.1288 |
0.415 |
|
| 2002 |
Bellm LA, Cunningham G, Durnell L, Eilers J, Epstein JB, Fleming T, Fuchs HJ, Haskins MN, Horowitz MM, Martin PJ, McGuire DB, Mullane K, Oster G. Defining clinically meaningful outcomes in the evaluation of new treatments for oral mucositis: oral mucositis patient provider advisory board. Cancer Investigation. 20: 793-800. PMID 12197238 DOI: 10.1081/Cnv-120002497 |
0.335 |
|
| 2000 |
Fleming TR, Lin DY. Survival Analysis in Clinical Trials: Past Developments and Future Directions Biometrics. 56: 971-983. PMID 11129494 DOI: 10.1111/J.0006-341X.2000.0971.X |
0.354 |
|
| 2000 |
Fleming TR. Surrogate end points in cardiovascular disease trials American Heart Journal. 139. PMID 10740130 DOI: 10.1016/S0002-8703(00)90071-1 |
0.391 |
|
| 2000 |
Fleming TR. Design and interpretation of equivalence trials. American Heart Journal. 139. PMID 10740126 DOI: 10.1016/S0002-8703(00)90067-X |
0.378 |
|
| 2000 |
Fleming TR. An FDA perspective on antiarrhythmic drugs in Phase II trials American Heart Journal. 139: 197-199. DOI: 10.1067/Mhj.2000.104179 |
0.308 |
|
| 1999 |
Psaty BM, Weiss NS, Furberg CD, Koepsell TD, Siscovick DS, Rosendaal FR, Smith NL, Heckbert SR, Kaplan RC, Lin D, Fleming TR, Wagner EH. Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. Jama. 282: 786-90. PMID 10463718 DOI: 10.1001/Jama.282.8.786 |
0.307 |
|
| 1999 |
Shen Y, Fleming TR. Assessing Effects on Long-term Survival after Early Termination of Randomized Trials Lifetime Data Analysis. 5: 55-66. PMID 10214002 DOI: 10.1023/A:1009631100455 |
0.353 |
|
| 1997 |
Rida W, Fast P, Hoff R, Fleming T. Intermediate-size trials for the evaluation of HIV vaccine candidates: a workshop summary. Journal of Acquired Immune Deficiency Syndromes. 16: 195-203. PMID 9390572 DOI: 10.1097/00042560-199711010-00009 |
0.329 |
|
| 1997 |
Lin DY, Fleming TR, De Gruttola V. Estimating the proportion of treatment effect explained by a surrogate marker. Statistics in Medicine. 16: 1515-27. PMID 9249922 DOI: 10.1002/(Sici)1097-0258(19970715)16:13<1515::Aid-Sim572>3.0.Co;2-1 |
0.319 |
|
| 1997 |
Shen YU, Fleming TR. Weighted Mean Survival Test Statistics: a Class of Distance Tests for Censored Survival Data Journal of the Royal Statistical Society Series B-Statistical Methodology. 59: 269-280. DOI: 10.1111/1467-9868.00068 |
0.318 |
|
| 1996 |
Martino RL, Fleming TR, Morrell LM, Ardalan B, Richman SP, Macdonald JS. Phase II trial of low-dose N-(phosphonacetyl)-disodium L-aspartic acid and high-dose 24-hour infusional 5-fluorouracil in advanced gastric adenocarcinoma. A Southwest Oncology Group study. Investigational New Drugs. 14: 419-21. PMID 9157080 DOI: 10.1007/Bf00180821 |
0.334 |
|
| 1996 |
Fleming TR, DeMets DL. Surrogate End Points in Clinical Trials: Are We Being Misled? Annals of Internal Medicine. 125: 605-613. PMID 8815760 DOI: 10.7326/0003-4819-125-7-199610010-00011 |
0.376 |
|
| 1996 |
Fleming TR. Surrogate Endpoints in Clinical Trials Drug Information Journal. 30: 545-551. DOI: 10.1177/009286159603000230 |
0.379 |
|
| 1995 |
DeMets DL, Fleming TR, Whitley RJ, Childress JF, Ellenberg SS, Foulkes M, Mayer KH, O'Fallon J, Pollard RB, Rahal JJ, Sande M, Straus S, Walters L, Whitley-Williams P. The Data and Safety Monitoring Board and Acquired immune deficiency syndrome (AIDS) clinical trials Controlled Clinical Trials. 16: 408-421. PMID 8720018 DOI: 10.1016/S0197-2456(95)00073-9 |
0.401 |
|
| 1995 |
Berenberg JL, Tangen C, Macdonald JS, Hutchins LF, Natale RB, Oishi N, Guy JT, Fleming TR. Phase II study of 5-fluorouracil and folinic acid in the treatment of patients with advanced gastric cancer. A Southwest Oncology Group study. Cancer. 76: 715-9. PMID 8625171 DOI: 10.1002/1097-0142(19950901)76:5<715::Aid-Cncr2820760502>3.0.Co;2-3 |
0.364 |
|
| 1995 |
Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, Ungerleider JS, Emerson WA, Tormey DC, Glick JH. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 13: 2936-43. PMID 8523058 DOI: 10.1200/Jco.1995.13.12.2936 |
0.392 |
|
| 1995 |
Leichman CG, Fleming TR, Muggia FM, Tangen CM, Ardalan B, Doroshow JH, Meyers FJ, Holcombe RF, Weiss GR, Mangalik A. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. Journal of Clinical Oncology. 13: 1303-1311. PMID 7751875 DOI: 10.1200/Jco.1995.13.6.1303 |
0.405 |
|
| 1995 |
Fabian C, Giri S, Estes N, Tangen CM, Poplin E, Vogel S, Goodwin W, Rivkin S, Fleming TR, Macdonald JS. Adjuvant continuous infusion 5-FU, whole-abdominal radiation, and tumor bed boost in high-risk stage III colon carcinoma: a Southwest Oncology Group Pilot study. International Journal of Radiation Oncology, Biology, Physics. 32: 457-64. PMID 7751186 DOI: 10.1016/0360-3016(94)00600-P |
0.35 |
|
| 1995 |
Fleming TR. Interpretation of Subgroup Analyses in Clinical Trials Drug Information Journal. 29. DOI: 10.1177/00928615950290S114 |
0.402 |
|
| 1995 |
Anderson GL, Fleming TR. Model misspecification in proportional hazards regression Biometrika. 82: 527-541. DOI: 10.1093/Biomet/82.3.527 |
0.331 |
|
| 1994 |
Bukowski RM, Tangen CM, Peterson RF, Taylor SA, Rinehart JJ, Eyre HJ, Rivkin SE, Fleming TR, Macdonald JS. Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group study. Cancer. 73: 1505-8. PMID 8111718 DOI: 10.1002/1097-0142(19940301)73:5<1505::Aid-Cncr2820730530>3.0.Co;2-V |
0.376 |
|
| 1994 |
Fleming TR, Prentice RL, Pepe MS, Glidden D. Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research Statistics in Medicine. 13: 955-968. PMID 8047747 DOI: 10.1002/Sim.4780130906 |
0.354 |
|
| 1994 |
Fleming TR. Surrogate markers in aids and cancer trials Statistics in Medicine. 13: 1423-1435. PMID 7973222 DOI: 10.1002/Sim.4780131318 |
0.384 |
|
| 1993 |
Fleming TR. Data monitoring committees and capturing relevant information of high quality Statistics in Medicine. 12: 565-570. PMID 8493432 DOI: 10.1002/Sim.4780120524 |
0.34 |
|
| 1993 |
Brown TD, Goodman PJ, Fleming T, Macdonald JS, Craig JB, Einstein AB. Phase II trial of amonafide in advanced colorectal cancer: a SouthWest Oncology Group study. Anti-Cancer Drugs. 4: 49-50. PMID 8457714 DOI: 10.1097/00001813-199302000-00006 |
0.397 |
|
| 1993 |
Bukowski RM, Fleming TR, Macdonald JS, Oishi N, Taylor SA, Baker LH. Evaluation of combination chemotherapy and phase II agents in pancreatic adenocarcinoma. A Southwest Oncology Group study. Cancer. 71: 322-5. PMID 8422624 DOI: 10.1002/1097-0142(19930115)71:2<322::Aid-Cncr2820710209>3.0.Co;2-G |
0.36 |
|
| 1993 |
Poplin E, Fleming T, MacDonald JS, Eisenberg P, Fisher RI, Conrad ME. Amonafide treatment of refractory esophageal cancer. A Southwest Oncology Group study. Investigational New Drugs. 11: 47-51. PMID 8349435 DOI: 10.1007/Bf00873910 |
0.355 |
|
| 1993 |
Fleming TR, DeMets DL. Monitoring of clinical trials: Issues and recommendations Controlled Clinical Trials. 14: 183-197. PMID 8339549 DOI: 10.1016/0197-2456(93)90002-U |
0.409 |
|
| 1993 |
Leichman CG, Tangen C, Macdonald JS, Leimert T, Fleming TR. Phase II trial of amonafide in advanced pancreas cancer. A Southwest Oncology Group study. Investigational New Drugs. 11: 219-21. PMID 8262735 DOI: 10.1007/Bf00874159 |
0.361 |
|
| 1993 |
Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA. Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 11: 2386-90. PMID 8246027 DOI: 10.1200/Jco.1993.11.12.2386 |
0.323 |
|
| 1993 |
KOSOROK MR, FLEMING TR. Using surrogate failure time data to increase cost effectiveness in clinical trials Biometrika. 80: 823-833. DOI: 10.1093/Biomet/80.4.823 |
0.552 |
|
| 1993 |
Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen C. An Evaluation of the Carcinoembryonic Antigen (CEA) Test for Monitoring Patients With Resected Colon Cancer Jama. 270: 943-947. DOI: 10.1001/Jama.1993.03510080047030 |
0.339 |
|
| 1992 |
Dickson ER, Murtaugh PA, Wiesner RH, Grambsch PM, Fleming TR, Ludwig J, LaRusso NF, Malinchoc M, Chapman RW, Kaplan MM, Maddrey WC, Williams R, Farrant M, Langworthy A. Primary sclerosing cholangitis: Refinement and validation of survival models Gastroenterology. 103: 1893-1901. PMID 1451982 DOI: 10.1016/0016-5085(92)91449-E |
0.333 |
|
| 1992 |
Bukowski RM, Tangen C, Lee R, Macdonald JS, Einstein AB, Peterson R, Fleming TR. Phase II trial of chlorozotocin and fluorouracil in islet cell carcinoma: a Southwest Oncology Group study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 10: 1914-8. PMID 1333517 DOI: 10.1200/Jco.1992.10.12.1914 |
0.349 |
|
| 1992 |
Kreiss J, Ngugi E, Holmes K, Ndinya-Achola J, Waiyaki P, Roberts PL, Ruminjo I, Sajabi R, Kimata J, Fleming TR, Anzala A, Holton D, Plummer F. Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. Jama. 268: 477-482. DOI: 10.1001/Jama.1992.03490040053025 |
0.309 |
|
| 1991 |
Brown TD, Goodman PJ, Fleming TR, Taylor SA, Macdonald JS. Phase II trial of echinomycin in advanced colorectal cancer. A Southwest Oncology Group study. Investigational New Drugs. 9: 113-4. PMID 2026480 DOI: 10.1007/Bf00194561 |
0.317 |
|
| 1991 |
Morrell LM, Bach A, Richman SP, Goodman P, Fleming TR, MacDonald JS. A phase II multi-institutional trial of low-dose N-(phosphonacetyl)-L-aspartate and high-dose 5-fluorouracil as a short-term infusion in the treatment of adenocarcinoma of the pancreas. A Southwest Oncology Group study. Cancer. 67: 363-6. PMID 1985731 DOI: 10.1002/1097-0142(19910115)67:2<363::Aid-Cncr2820670208>3.0.Co;2-H |
0.354 |
|
| 1991 |
Brown TD, Goodman PJ, Fleming TR, Baker LH, Macdonald JS. Phase II trial of menogaril in adenocarcinoma of the pancreas. A Southwest Oncology Group study. Investigational New Drugs. 9: 77-8. PMID 1827433 DOI: 10.1007/Bf00194550 |
0.325 |
|
| 1991 |
Whitehead RP, Fleming TR, Macdonald JS, Ahmann FR, Garewal HS, Kuebler JP. A phase II study of chemotherapy of metastatic colorectal carcinoma with 5-fluorouracil plus cisplatin. A Southwest Oncology Group study. Investigational New Drugs. 9: 345-7. PMID 1804811 DOI: 10.1007/Bf00183578 |
0.351 |
|
| 1991 |
Brown TD, Goodman PJ, Fleming T, Macdonald JS, O'Rourke T, Taylor SA, Neefe JR, Gaynor E. Phase II trial of recombinant DNA gamma-interferon in advanced colorectal cancer: a Southwest Oncology Group study. Journal of Immunotherapy : Official Journal of the Society For Biological Therapy. 10: 379-82. PMID 1790147 DOI: 10.1097/00002371-199110000-00011 |
0.346 |
|
| 1991 |
Brown TD, Goodman P, Fleming T, Macdonald JS, Hersh EM, Braun TJ. A phase II trial of recombinant tumor necrosis factor in patients with adenocarcinoma of the pancreas: a Southwest Oncology Group study. Journal of Immunotherapy : Official Journal of the Society For Biological Therapy. 10: 376-8. PMID 1790146 DOI: 10.1097/00002371-199110000-00010 |
0.375 |
|
| 1991 |
Kraut EH, Fleming T, Segal M, Neidhart JA, Behrens BC, MacDonald J. Phase II study of pibenzimol in pancreatic cancer. A Southwest Oncology Group study. Investigational New Drugs. 9: 95-96. PMID 1709154 DOI: 10.1007/Bf00194556 |
0.313 |
|
| 1990 |
Oishi N, Fleming TR, Laufman L, Ungerleider JS, Natale RB, Einstein AB, Von Hoff DD, Macdonald JS. VM-26 in colorectal carcinoma: a Southwest Oncology Group study. Investigational New Drugs. 8: 93-5. PMID 2188930 DOI: 10.1007/Bf00216931 |
0.345 |
|
| 1990 |
Vaughn CB, Salmon SE, Fleming TR. Phase II evaluation of esorubicin (4'deoxydoxorubicin) in pancreatic adenocarcinoma: a Southwest Oncology Group study. Investigational New Drugs. 8: 81-85. PMID 2188929 DOI: 10.1007/Bf00216929 |
0.337 |
|
| 1990 |
Whitehead RP, Earhart RH, Fleming T, Goodman P, Macdonald JS, Pollock T, Ungerleider JS. A phase II study of menogaril (NSC-269148) in colorectal carcinoma. A Southwest Oncology Group study. Investigational New Drugs. 8: 295-7. PMID 2148743 DOI: 10.1007/Bf00171840 |
0.359 |
|
| 1989 |
Laurie JA, Moertel CG, Fleming TR, Wieand HS, Leigh JE, Rubin J, McCormack GW, Gerstner JB, Krook JE, Malliard J. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. Journal of Clinical Oncology. 7: 1447-1456. PMID 2778478 DOI: 10.1200/Jco.1989.7.10.1447 |
0.353 |
|
| 1989 |
Wiesner RH, Grambsch PM, Dickson ER, Ludwig J, MacCarty RL, Hunter EB, Fleming TR, Fisher LD, Beaver SJ, LaRusso NF. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology (Baltimore, Md.). 10: 430-6. PMID 2777204 DOI: 10.1002/Hep.1840100406 |
0.332 |
|
| 1989 |
Dickson ER, Grambsch PM, Fleming TR, Fisher LD, Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology (Baltimore, Md.). 10: 1-7. PMID 2737595 DOI: 10.1002/Hep.1840100102 |
0.303 |
|
| 1989 |
Grambsch PM, Dickson ER, Kaplan M, Lesage G, Fleming TR, Langworthy AL. Extramural cross-validation of the Mayo primary biliary cirrhosis survival model establishes its generalizability. Hepatology. 10: 846-850. PMID 2680867 DOI: 10.1002/Hep.1840100516 |
0.304 |
|
| 1987 |
Green SJ, Fleming TR, O'Fallon JR. Policies for study monitoring and interim reporting of results. Journal of Clinical Oncology. 5: 1477-1484. PMID 3625262 DOI: 10.1200/Jco.1987.5.9.1477 |
0.363 |
|
| 1987 |
Green SJ, Fleming TR, Emerson S. Effects on overviews of early stopping rules for clinical trials Statistics in Medicine. 6: 361-367. PMID 3616289 DOI: 10.1002/Sim.4780060329 |
0.384 |
|
| 1987 |
Poplin E, Fleming T, Leichman L, Seydel HG, Steiger Z, Taylor S, Vance R, Stuckey WJ, Rivkin SE. Combined therapies for squamous-cell carcinoma of the esophagus, a Southwest Oncology Group Study (SWOG-8037). Journal of Clinical Oncology. 5: 622-628. PMID 3559653 DOI: 10.1200/Jco.1987.5.4.622 |
0.338 |
|
| 1985 |
Dickson ER, Fleming TR, Wiesner RH, Baldus WP, Fleming CR, Ludwig J, McCall JT. Trial of penicillamine in advanced primary biliary cirrhosis. The New England Journal of Medicine. 312: 1011-5. PMID 3885033 DOI: 10.1056/NEJM198504183121602 |
0.31 |
|
| 1985 |
Moertel CG, Fleming TR, Creagan ET, Rubin J, O'Connell MJ, Ames MM. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. The New England Journal of Medicine. 312: 137-141. PMID 3880867 DOI: 10.1056/Nejm198501173120301 |
0.359 |
|
| 1985 |
Krook JE, Jett JR, Fleming TR, Dalton RJ, Marschke RF, Cullinan SA, Windschitl HE, Everson LK, Brunk FS, Laurie JA. A controlled evaluation of combined 5-fluorouracil, doxorubicin, and mitomycin C (FAM) for the treatment of advanced non-small-cell lung cancer Journal of Clinical Oncology. 3: 842-848. PMID 3839263 DOI: 10.1200/Jco.1985.3.6.842 |
0.325 |
|
| 1985 |
Buroker TR, Moertel CG, Fleming TR, Everson LK, Cullinan SA, Krook JE, Mailliard JA, Marschke RF, Klaassen DJ, Laurie JA. A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma. Journal of Clinical Oncology. 3: 1624-1631. PMID 2933492 DOI: 10.1200/Jco.1985.3.12.1624 |
0.326 |
|
| 1985 |
Cullinan SA, Moertel CG, Fleming TR, Rubin JR, Krook JE, Everson LK, Windschitl HE, Twito DI, Marschke RF, Foley JF, Pfeifle DM, Barlow JF. A Comparison of Three Chemotherapeutic Regimens in the Treatment of Advanced Pancreatic and Gastric Carcinoma: Fluorouracil vs Fluorouracil and Doxorubicin vs Fluorouracil, Doxorubicin, and Mitomycin Jama. 253: 2061-2067. DOI: 10.1001/Jama.1985.03350380077025 |
0.324 |
|
| 1984 |
Fleming TR, Green SJ, Harrington DP. Considerations for monitoring and evaluating treatment effects in clinical trials Controlled Clinical Trials. 5: 55-66. PMID 6713908 DOI: 10.1016/0197-2456(84)90150-8 |
0.389 |
|
| 1984 |
Edmonson JH, Fleming TR, Ivins JC, Burgert EO, Soule EH, O'Connell MJ, Sim FH, Ahmann DL. Randomized study of systemic chemotherapy following complete excision of nonosseous sarcomas. Journal of Clinical Oncology. 2: 1390-1396. PMID 6512582 DOI: 10.1200/Jco.1984.2.12.1390 |
0.368 |
|
| 1983 |
Myers RP, Zincke H, Fleming TR, Farrow GM, Furlow WL, Utz DC. Hormonal treatment at time of radical retropubic prostatectomy for stage D1 prostate cancer. The Journal of Urology. 130: 99-101. PMID 6864924 DOI: 10.1016/S0022-5347(17)50979-9 |
0.307 |
|
| 1982 |
Fleming TR. One-Sample Multiple Testing Procedure for Phase II Clinical Trials Biometrics. 38: 143-151. DOI: 10.2307/2530297 |
0.342 |
|
| 1982 |
Moertel CG, Fleming TR, Rubin J, Kvols LK, Sarna G, Koch R, Currie VE, Young CW, Jones SE, Davignon JP. Tumors, Including Endometriosis: A Clinical Trial of Amygdalin (laetrile) in the Treatment of Human Cancer Obstetrical & Gynecological Survey. 37: 433-434. DOI: 10.1097/00006254-198206000-00028 |
0.335 |
|
| 1981 |
Zincke H, Fleming TR, Furlow WL, Myers RP, Utz DC. Radical retropubic prostatectomy and pelvic lymphadenectomy for high-stage cancer of the prostate Cancer. 47: 1901-1910. PMID 7226084 DOI: 10.1002/1097-0142(19810401)47:7<1901::Aid-Cncr2820470731>3.0.Co;2-N |
0.314 |
|
| 1981 |
Creagan ET, Fleming TR, Edmonson JH, Ingle JN, Woods JE. Chemotherapy for advanced head and neck cancer with the combination adriamycin, cyclophosphamide, and cis-diamminedichloroplatinum (II): Preliminary assessment of a one-day vs. three-day drug regimen Cancer. 47: 2549-2551. PMID 7196281 DOI: 10.1002/1097-0142(19810601)47:11<2549::Aid-Cncr2820471105>3.0.Co;2-H |
0.312 |
|
| 1981 |
Creagan ET, Fleming TR, Edmonson JH, Ingle JN, Woods JE. Cyclophosphamide, adriamycin, and cis-diamminedichloroplatinum (II) in the treatment of patients with advanced head and neck cancer Cancer. 47: 240-244. PMID 7193079 DOI: 10.1002/1097-0142(19810115)47:2<240::Aid-Cncr2820470206>3.0.Co;2-7 |
0.374 |
|
| 1981 |
Lininger TR, Fleming TR, Eagan RT. Evaluation of alternating chemotherapy and sites and extent of disease in extensive small cell lung cancer. Cancer. 48: 2147-2153. PMID 6271381 DOI: 10.1002/1097-0142(19811115)48:10<2147::Aid-Cncr2820481005>3.0.Co;2-S |
0.333 |
|
| 1980 |
Eagan RT, Fleming TR, Lee RE, Ingle JN, Frytak S, Creagan ET. Chemotherapy response as a prognosticator for survival in patients with limited squamous cell lung cancer treated with combined chemotherapy and radiotherapy International Journal of Radiation Oncology Biology Physics. 6: 879-883. PMID 7204125 DOI: 10.1016/0360-3016(80)90328-4 |
0.34 |
|
| 1980 |
Cupps RE, Utz DC, Fleming TR, Carson CC, Zincke H, Myers RP. Definitive Radiation Therapy for Prostatio Carcinoma: Mayo Clinic Experience The Journal of Urology. 124: 855-859. PMID 6777510 DOI: 10.1016/S0022-5347(17)55700-6 |
0.318 |
|
| 1979 |
Creagan ET, Fleming TR, Edmonson JH, Pairolero PC. Pulmonary resection for metastatic nonosteogenic sarcoma Cancer. 44: 1908-1912. PMID 498056 DOI: 10.1002/1097-0142(197911)44:5<1908::Aid-Cncr2820440553>3.0.Co;2-2 |
0.322 |
|
| 1979 |
Eagan RT, Fleming TR, Schoonover V. Evaluation of response criteria in advanced lung cancer. Cancer. 44: 1125-1128. PMID 476590 DOI: 10.1002/1097-0142(197909)44:3<1125::Aid-Cncr2820440348>3.0.Co;2-4 |
0.312 |
|
| 1979 |
Eagan RT, Lee RE, Frytak S, Fleming TR, Cregan ET, Ingle JN, Kvols LK. Randomized trial of thoracic irradiation plus combination chemotherapy for unresectable adenocarcinoma and large cell carcinoma of the lung. International Journal of Radiation Oncology Biology Physics. 5: 1401-1405. PMID 231024 DOI: 10.1016/0360-3016(79)90678-3 |
0.368 |
|
| 1979 |
O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 35: 549-556. DOI: 10.2307/2530245 |
0.31 |
|
| 1979 |
Eagan RT, Creagan ET, Ingle JN, Rubin J, Frytak S, Kvols LK, Fleming TR. VP-16, cyclophosphamide, adriamycin and cis-platinum (V:CAP-I) in patients with metastatic adenocarcinoma of the lung. Tumori. 65: 105-109. DOI: 10.1177/030089167906500112 |
0.31 |
|
| 1979 |
Eagan RT, Childs DS, Layton DD, Laws ER, Bisel HF, Holbrook MA, Fleming TR. Dianhydrogalactitol and Radiation Therapy: Treatment of Supratentorial Glioma Jama. 241: 2046-2050. DOI: 10.1001/Jama.1979.03290450044023 |
0.347 |
|
| Show low-probability matches. |